Trial Outcomes & Findings for Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients (NCT NCT01348100)

NCT ID: NCT01348100

Last Updated: 2014-01-22

Results Overview

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

• Recruitment status: COMPLETED
• Study phase: PHASE1/PHASE2
• Target enrollment: 81 participants
• Primary outcome timeframe: Pre-dose to 26 days post-dose
• Results posted on: 2014-01-22

Participant Flow

Participant milestones

Measure	Iloperidone 50 mg Crystalline Formulation - Phase A Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.	Iloperidone 125 mg Crystalline Formulation - Phase A Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Crystalline Formulation - Phase B Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 500 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Overall Study STARTED	2	2	15	15	15	16	16
Overall Study COMPLETED	2	2	13	14	14	14	13
Overall Study NOT COMPLETED	0	0	2	1	1	2	3

Reasons for withdrawal

Measure	Iloperidone 50 mg Crystalline Formulation - Phase A Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.	Iloperidone 125 mg Crystalline Formulation - Phase A Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Crystalline Formulation - Phase B Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 500 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Overall Study Subject Withdrew Consent	0	0	2	0	1	0	1
Overall Study Protocol Deviation	0	0	0	1	0	0	0
Overall Study Unsatisfactory Therapeutic Effect	0	0	0	0	0	1	0
Overall Study Lost to Follow-up	0	0	0	0	0	0	1
Overall Study Administrative Problems	0	0	0	0	0	1	1

Baseline Characteristics

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

Baseline characteristics by cohort

Measure	Iloperidone 50 mg Crystalline Formulation - Phase A n=2 Participants Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.	Iloperidone 125 mg Crystalline Formulation - Phase A n=2 Participants Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Crystalline Formulation - Phase B n=15 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=15 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase C n=15 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 500 mg Microparticle Formulation - Phase C n=16 Participants Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C n=16 Participants Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Total n=81 Participants Total of all reporting groups
Age, Continuous	42.0 years STANDARD_DEVIATION 2.83 • n=5 Participants	35.5 years STANDARD_DEVIATION 12.02 • n=7 Participants	45.5 years STANDARD_DEVIATION 14.81 • n=5 Participants	43.5 years STANDARD_DEVIATION 13.02 • n=4 Participants	42.3 years STANDARD_DEVIATION 10.62 • n=21 Participants	41.3 years STANDARD_DEVIATION 10.03 • n=10 Participants	45.1 years STANDARD_DEVIATION 11.21 • n=115 Participants	43.3 years STANDARD_DEVIATION 11.60 • n=24 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	2 Participants n=7 Participants	5 Participants n=5 Participants	4 Participants n=4 Participants	6 Participants n=21 Participants	5 Participants n=10 Participants	3 Participants n=115 Participants	25 Participants n=24 Participants
Sex: Female, Male Male	2 Participants n=5 Participants	0 Participants n=7 Participants	10 Participants n=5 Participants	11 Participants n=4 Participants	9 Participants n=21 Participants	11 Participants n=10 Participants	13 Participants n=115 Participants	56 Participants n=24 Participants

PRIMARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=13 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Maximum Observed Plasma Concentration (Cmax) of Iloperidone Divided by the Average Plasma Concentration (Cav) of Iloperidone (Cmax/Cav) - Phase B	1.91 Ratio of Cmax to Cav Standard Deviation 0.513	1.87 Ratio of Cmax to Cav Standard Deviation 0.554	—

PRIMARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. Blood samples were collected after each depot injection. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Cav was calculated as AUC0-672h/672 h.

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=15 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C n=14 Participants Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
The Average Plasma Concentration (Cav) of Iloperidone - Phase C Dose 1 - n = 15, 13, 12	3.73 ng/mL Standard Deviation 1.16	7.93 ng/mL Standard Deviation 5.29	11.8 ng/mL Standard Deviation 8.10
The Average Plasma Concentration (Cav) of Iloperidone - Phase C Dose 2 - n = 14, 14, 13	4.52 ng/mL Standard Deviation 1.50	10.1 ng/mL Standard Deviation 5.46	16.0 ng/mL Standard Deviation 7.12

SECONDARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=13 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Time to Reach the Maximum Plasma Concentration (Tmax) of Iloperidone - Phase B	48.1 hours Interval 0.0 to 169.0	168 hours Interval 6.0 to 434.0	—

SECONDARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=13 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Maximum Observed Plasma Concentration (Cmax) of Iloperidone - Phase B	6.25 ng/mL Standard Deviation 2.98	8.40 ng/mL Standard Deviation 3.49	—

SECONDARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. The area under the curve was calculated using a linear trapezoidal method. The end of the dosing period was 672 hours (28 days).

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=13 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Area Under the Plasma Concentration-time Curve From 0 to the End of the Dosing Period (AUCtau) of Iloperidone - Phase B	2310 ng*h/mL Standard Deviation 1170	3190 ng*h/mL Standard Deviation 1670	—

SECONDARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. The area under the curve was calculated using a linear trapezoidal method.

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=13 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Area Under the Plasma Concentration-time Curve From 0 to the Last Measurable Concentration (AUClast) of Iloperidone - Phase B	2890 ng*h/mL Standard Deviation 1380	3730 ng*h/mL Standard Deviation 1730	—

SECONDARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Cav was calculated as AUC0-672h/672 h.

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=13 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
The Average Plasma Concentration (Cav) of Iloperidone - Phase B	3.44 ng/mL Standard Deviation 1.74	4.74 ng/mL Standard Deviation 2.49	—

SECONDARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. The duration that the concentration of iloperidone was above 4 ng/mL was calculated by linear interpolation. PK/pharmacodynamic analysis performed in other studies suggests that iloperidone plasma levels of 4 ng/mL or above provide clinical efficacy.

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=13 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Duration That the Concentration of Iloperidone Was Above 4 ng/mL (Teff) - Phase B	150 hours Interval 0.0 to 714.0	365 hours Interval 0.0 to 801.0	—

SECONDARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. Blood samples were collected after each depot injection. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=15 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C n=14 Participants Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Time to Reach the Maximum Plasma Concentration (Tmax) of Iloperidone - Phase C Dose 1 - n = 15, 14, 14	48 hours Interval 3.0 to 506.0	227 hours Interval 3.0 to 601.0	192 hours Interval 24.0 to 672.0
Time to Reach the Maximum Plasma Concentration (Tmax) of Iloperidone - Phase C Dose 2 - n = 14, 14, 13	48 hours Interval 24.0 to 266.0	207 hours Interval 36.0 to 600.0	195 hours Interval 48.0 to 385.0

SECONDARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. Blood samples were collected after each depot injection. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=15 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C n=14 Participants Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Maximum Observed Plasma Concentration (Cmax) of Iloperidone - Phase C Dose 1 - n = 15, 14, 14	6.45 ng/mL Standard Deviation 2.29	15.2 ng/mL Standard Deviation 13.9	19.7 ng/mL Standard Deviation 15.8
Maximum Observed Plasma Concentration (Cmax) of Iloperidone - Phase C Dose 2 - n = 14, 14, 13	8.15 ng/mL Standard Deviation 2.98	21.6 ng/mL Standard Deviation 19.6	29.2 ng/mL Standard Deviation 16.4

SECONDARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. Blood samples were collected after each depot injection. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. The area under the curve was calculated using a linear trapezoidal method. The end of the dosing period was 672 hours (28 days).

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=15 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C n=14 Participants Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
Area Under the Plasma Concentration-time Curve From 0 to the End of the Dosing Period (AUCtau) of Iloperidone - Phase C Dose 1 - n = 15, 13, 12	2500 ng*h/mL Standard Deviation 780	5330 ng*h/mL Standard Deviation 3560	7930 ng*h/mL Standard Deviation 5440
Area Under the Plasma Concentration-time Curve From 0 to the End of the Dosing Period (AUCtau) of Iloperidone - Phase C Dose 2 - n = 14, 14, 13	3040 ng*h/mL Standard Deviation 1010	6820 ng*h/mL Standard Deviation 3670	10700 ng*h/mL Standard Deviation 4790

SECONDARY outcome

Timeframe: Pre-dose to 26 days post-dose

Population: Pharmacokinetic population: All participants with evaluable pharmacokinetic data.

Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. Blood samples were collected after each depot injection. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Cav was calculated as AUC0-672h/672 h.

Outcome measures

Measure	Iloperidone 250 mg Crystalline Formulation - Phase B n=15 Participants Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B n=14 Participants Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C n=14 Participants Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
The Average Plasma Concentration (Cav) of Iloperidone Divided by Dose - Phase C Dose 1 - n = 15, 13, 12	0.0156 ng/mL/mg Standard Deviation 0.00464	0.0172 ng/mL/mg Standard Deviation 0.0107	0.0196 ng/mL/mg Standard Deviation 0.0125
The Average Plasma Concentration (Cav) of Iloperidone Divided by Dose - Phase C Dose 2 - n = 14, 14, 13	0.0300 ng/mL/mg Standard Deviation 0.0235	0.0242 ng/mL/mg Standard Deviation 0.0129	0.0328 ng/mL/mg Standard Deviation 0.0141

Adverse Events

Iloperidone 50 mg Crystalline Formulation - Phase A Oral

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Iloperidone 125 mg Crystalline Formulation - Phase A Oral

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Iloperidone 50 mg Crystalline Formulation - Phase A Depot

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Iloperidone 125 mg Crystalline Formulation - Phase A Depot

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Iloperidone 250 mg Crystalline Formulation - Phase B Oral

Serious events: 0 serious events

Other events: 9 other events

Deaths: 0 deaths

Iloperidone 250 mg Microparticle Formulation - Phase B Oral

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

Iloperidone 250 mg Crystalline Formulation - Phase B Depot

Serious events: 2 serious events

Other events: 4 other events

Deaths: 0 deaths

Iloperidone 250 mg Microparticle Formulation - Phase B Depot

Serious events: 1 serious events

Other events: 8 other events

Deaths: 0 deaths

Iloperidone 250 mg Microparticle Formulation - Phase C Oral

Serious events: 0 serious events

Other events: 11 other events

Deaths: 0 deaths

Iloperidone 500 mg Microparticle Formulation - Phase C Oral

Serious events: 0 serious events

Other events: 9 other events

Deaths: 0 deaths

Iloperidone 625 mg Microparticle Formulation - Phase C Oral

Serious events: 0 serious events

Other events: 9 other events

Deaths: 0 deaths

Iloperidone 250 mg Microparticle Formulation - Phase C Depot

Serious events: 0 serious events

Other events: 13 other events

Deaths: 0 deaths

Iloperidone 500 mg Microparticle Formulation - Phase C Depot

Serious events: 0 serious events

Other events: 12 other events

Deaths: 0 deaths

Iloperidone 625 mg Microparticle Formulation - Phase C Depot

Serious events: 0 serious events

Other events: 13 other events

Deaths: 0 deaths

Serious adverse events

Measure	Iloperidone 50 mg Crystalline Formulation - Phase A Oral n=2 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.	Iloperidone 125 mg Crystalline Formulation - Phase A Oral n=2 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.	Iloperidone 50 mg Crystalline Formulation - Phase A Depot n=2 participants at risk Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time.	Iloperidone 125 mg Crystalline Formulation - Phase A Depot n=2 participants at risk Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time.	Iloperidone 250 mg Crystalline Formulation - Phase B Oral n=15 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B Oral n=15 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Crystalline Formulation - Phase B Depot n=14 participants at risk Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time.	Iloperidone 250 mg Microparticle Formulation - Phase B Depot n=14 participants at risk Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time.	Iloperidone 250 mg Microparticle Formulation - Phase C Oral n=15 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 500 mg Microparticle Formulation - Phase C Oral n=15 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Oral n=15 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase C Depot n=15 participants at risk Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart.	Iloperidone 500 mg Microparticle Formulation - Phase C Depot n=15 participants at risk Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart.	Iloperidone 625 mg Microparticle Formulation - Phase C Depot n=15 participants at risk Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart.
Nervous system disorders Extrapyramidal disorder	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Social circumstances Social stay hospitalisation	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Psychotic disorder	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	14.3% 2/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Surgical and medical procedures Hospitalisation	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.

Other adverse events

Measure	Iloperidone 50 mg Crystalline Formulation - Phase A Oral n=2 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.	Iloperidone 125 mg Crystalline Formulation - Phase A Oral n=2 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.	Iloperidone 50 mg Crystalline Formulation - Phase A Depot n=2 participants at risk Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time.	Iloperidone 125 mg Crystalline Formulation - Phase A Depot n=2 participants at risk Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time.	Iloperidone 250 mg Crystalline Formulation - Phase B Oral n=15 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase B Oral n=15 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Crystalline Formulation - Phase B Depot n=14 participants at risk Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time.	Iloperidone 250 mg Microparticle Formulation - Phase B Depot n=14 participants at risk Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time.	Iloperidone 250 mg Microparticle Formulation - Phase C Oral n=15 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 500 mg Microparticle Formulation - Phase C Oral n=15 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 625 mg Microparticle Formulation - Phase C Oral n=15 participants at risk Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.	Iloperidone 250 mg Microparticle Formulation - Phase C Depot n=15 participants at risk Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart.	Iloperidone 500 mg Microparticle Formulation - Phase C Depot n=15 participants at risk Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart.	Iloperidone 625 mg Microparticle Formulation - Phase C Depot n=15 participants at risk Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart.
General disorders Malaise	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Gastrointestinal disorders Diarrhoea	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Dysphoria	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Hallucination, auditory	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Insomnia	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	20.0% 3/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	33.3% 5/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Ear and labyrinth disorders Vertigo	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Eye disorders Vision blurred	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Gastrointestinal disorders Constipation	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	50.0% 1/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	14.3% 2/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Gastrointestinal disorders Dry mouth	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Gastrointestinal disorders Dyspepsia	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Gastrointestinal disorders Nausea	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Gastrointestinal disorders Tongue disorder	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Gastrointestinal disorders Toothache	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Gastrointestinal disorders Vomiting	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Chest pain	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Chills	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Fatigue	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Generalised oedema	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Injection site erythema	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Influenza like illness	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Injection site discharge	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Injection site exfoliation	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Injection site induration	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	26.7% 4/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	60.0% 9/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Injection site joint pain	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Injection site mass	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Injection site nodule	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Injection site pain	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	53.3% 8/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	60.0% 9/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	66.7% 10/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Injection site pruritus	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Injection site swelling	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	20.0% 3/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	20.0% 3/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Oedema peripheral	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
General disorders Pain	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Immune system disorders Hypersensitivity	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Infections and infestations Cellulitis	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Infections and infestations Ear infection	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Infections and infestations Nasopharyngitis	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Infections and infestations Subcutaneous abscess	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Infections and infestations Tooth abscess	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Dissociation	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Infections and infestations Upper respiratory tract infection	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	50.0% 1/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Infections and infestations Urinary tract infection	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Injury, poisoning and procedural complications Thermal burn	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Investigations Alanine aminotransferase increased	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Investigations Aspartate aminotransferase increased	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Investigations Blood creatine phosphokinase increased	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	50.0% 1/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Investigations Weight increased	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Metabolism and nutrition disorders Fluid retention	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Metabolism and nutrition disorders Increased appetite	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Nervous system disorders Akathisia	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Nervous system disorders Dizziness	50.0% 1/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Nervous system disorders Extrapyramidal disorder	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Nervous system disorders Headache	50.0% 1/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	33.3% 5/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	14.3% 2/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	26.7% 4/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	20.0% 3/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	26.7% 4/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Nervous system disorders Oromandibular dystonia	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Nervous system disorders Somnolence	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Pregnancy, puerperium and perinatal conditions Pregnancy	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Agitation	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Anxiety	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Libido decreased	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Obsessive thoughts	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Paranoia	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Psychotic disorder	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Psychiatric disorders Restlessness	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Azoospermia	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Dysmenorrhoea	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Ejaculation disorder	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Ejaculation failure	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Erectile dysfunction	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Haematospermia	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Painful ejaculation	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Priapism	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Pruritus genital	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Retrograde ejaculation	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Sexual dysfunction	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Testicular pain	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Uterine haemorrhage	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Reproductive system and breast disorders Vaginal odour	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	7.1% 1/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	40.0% 6/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	33.3% 5/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	20.0% 3/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	26.7% 4/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	13.3% 2/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Respiratory, thoracic and mediastinal disorders Painful respiration	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Respiratory, thoracic and mediastinal disorders Throat irritation	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	50.0% 1/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Skin and subcutaneous tissue disorders Dermatitis contact	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	50.0% 1/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Skin and subcutaneous tissue disorders Rash	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Skin and subcutaneous tissue disorders Skin irritation	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	50.0% 1/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Surgical and medical procedures Bone lesion excision	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Vascular disorders Hypotension	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.
Cardiac disorders Tachycardia	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/2 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/14 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	6.7% 1/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.	0.00% 0/15 • Adverse events were collected from Baseline to the end of the study. Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. One participant each in the Iloperidone 500 mg Microparticle Formulation - Phase C and the Iloperidone 625 mg Microparticle Formulation - Phase C groups did not receive iloperidone.

Additional Information

Study Director

Novartis Pharmaceuticals

Phone: 862 778-8300

Results disclosure agreements

• Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
• Publication restrictions are in place

Restriction type: OTHER